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a b s t r a c t
Serum was analyzed from 146 healthy adult volunteers in eastern Africa to evaluate measles virus (MV)
and canine distemper virus (CDV) neutralizing antibody (nAb) prevalence and potency. MV plaque
reduction neutralization test (PRNT) results indicated that all sera were positive for MV nAbs.
Furthermore, the 50% neutralizing dose (ND50) for the majority of sera corresponded to antibody titers
induced by MV vaccination. CDV nAbs titers were low and generally were detected in sera with high MV
nAb titers. A mutant CDV was generated that was less sensitive to neutralization by human serum. The
mutant virus genome had 10 nucleotide substitutions, which coded for single amino acid substitutions in
the fusion (F) and hemagglutinin (H) glycoproteins and two substitutions in the large polymerase
(L) protein. The H substitution occurred in a conserved region involved in receptor interactions among
morbilliviruses, implying that this region is a target for cross-reactive neutralizing antibodies.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Canine distemper virus (CDV) is a member of the Morbillivirus
genus, which also includes measles virus (MV), rinderpest virus (RPV),
peste des petits ruminants virus and morbilliviruses that infect aquatic
mammals (Blixenkrone-Moller, 1993; Di Guardo et al., 2005). These
related viruses generally each have a restricted natural host range. For
example MV infects humans, RPV infects cattle and other even-toed
ungulates, and CDV infects a variety of carnivorous animals. However,
CDV infection has been observed in monkey colonies indicating that its
host range can extend to primates (Qiu et al., 2011; Sakai et al., 2013a),
but so far, there is no conclusive evidence linking CDV to human
disease in spite of its speculative association to illness of unknown
etiology (Rima and Duprex, 2006). Lab-adapted CDV has been injected
into humans without causing symptoms of infection suggesting that
humans are not a permissive host for the virus (Hoekenga et al., 1960),
which is consistent with recent studies showing that mutations
facilitating both entry and replication are needed for CDV to efﬁciently
adapt to human cells (Otsuki et al., 2013; Sakai et al., 2013b). Prevalent
MV immunity induced by universal vaccination or natural infections
might also play a role in preventing CDV from crossing the human
barrier (de Vries et al., 2014). Despite considerable characterization of
antigenic and immunological relationships between CDV and MV
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(Haile et al., 1982; Orvell and Norrby, 1974, 1980; Stephenson and ter
Meulen, 1979), CDV neutralizing antibodies (nAbs) in humans have not
been extensively investigated.
Morbilliviruses are attractive candidates for development of
replication-competent vectors because modiﬁed live vaccines (e.g.
MV, CDV, and RPV) have proven to be very safe and efﬁcacious
(Buczkowski et al., 2014), and promising preclinical results have
been generated with a number of experimental vectors (Brandler
et al., 2007; Brandler and Tangy, 2008; Despres et al., 2005;
Gauvrit et al., 2008; Guerbois et al., 2009; Miest and Cattaneo,
2014; Wang et al., 2012). Morbilliviruses seem particularly rele-
vant for development of replication-competent AIDS vaccine
vectors since this genera of viruses replicates in lymphoid tissues
like HIV (Draper and Heeney, 2010; Koff et al., 2013; Parks et al.,
2013). Pre-existing MV immunity may interfere with use of MV
vectors, and unlike other viral vector systems in which rare
serotype viruses can be used as vector alternatives (Mingozzi
et al., 2013; Santra et al., 2009), MV has just one serotype. Thus,
CDV has been considered as a MV alternative to minimize the
effect of widespread anti-MV antibodies (Miest et al., 2011; Zhang
et al., 2013b). Because antibodies speciﬁc to MV do cross-react
with CDV (Appel et al., 1984; de Vries et al., 2014; Rima, 1983;
Taylor et al., 1991), it is important to evaluate the prevalence and
potency of CDV neutralizing activity in humans.
In this study, 146 serum samples collected from healthy adults
in three eastern Africa countries were surveyed for both MV and
CDV nAbs. We found that MV nAbs were prevalent in these
samples while the frequency of samples with signiﬁcant CDV
nAb titers was low. Moreover, when CDV neutralizing activity
was detected, it correlated with high anti-MV titers. We also used
human anti-serum to derive an in vitro escape mutant CDV strain
with increased resistance to neutralization. Genomic sequence
analysis of the resistant strain revealed an amino acid substitution
in a conserved region of the MV and CDV hemagglutinin
(H) proteins that may help identify the domain recognized by
cross-reactive nAbs and aide in future design H variants that are
less sensitive to the effect of anti-vector immunity.
Results
MV nAbs in African serum samples
Serum was collected from 146 healthy adult male and female
volunteers between 19 and 50 years of age (Table 1). The
volunteers were participants in vaccine trial preparedness cohorts
(Kamali et al., 2014) enrolled at 5 clinical research centers (CRCs)
supported by IAVI in Kenya (Kiliﬁ and Nairobi), Rwanda (Kigali),
and Uganda (Masaka and Entebbe).
The threshold for MV nAb positivity was deﬁned as average
ND50 titer of naïve macaque serum plus 3 times standard
deviation. When the PRNT was performed with the naïve macaque
serum control, the threshold was calculated as 8.63. All serum
samples from African volunteers were positive for MV nAbs since
their titers were above this threshold (Fig. 1) and the ND50 values
ranged from 16.0 to 6270. For comparison, serum analyzed from a
monkey vaccinated with an MV vaccine had an ND50 value of
1446 and earlier studies in college students indicated that ND50
titers below 120 do not prevent measles (Chen et al., 1990).
Overall, 77.4% of the African serum MV ND50 values fell between
120 and 2000, which is approximately equivalent to 300–5000
milli-International Units (mIU) of WHO international standard MV
antibodies (Cohen et al., 2007). The 300–5000 mIU range is
consistent with MV nAb levels induced by routine vaccination
(Hussain et al., 2013; Leuridan et al., 2010), suggesting that these
volunteers probably were vaccinated, although an MV vaccination
history was not available to conﬁrm this. Thirteen percent of the
samples exhibited MV ND50 titers above 2000, which was
indicative of a stronger response than typically observed after
vaccination suggesting that some volunteers had contracted
measles at some point (Leuridan et al., 2010). No signiﬁcant
difference in ND50 titers was observed across gender or age
groups. Overall antibody titers were similar among the regions
except for Nairobi where volunteers exhibited signiﬁcantly lower
titers than other regions (p¼0.01).
Generally low CDV nAbs titers in African serum samples and their
correlation with the magnitude of MV nAbs
When the CDV PRNT was performed with naïve ferret serum,
the average CDV ND50 titer plus 3 times standard deviation was
determined to be 29.29, which we employed as our threshold for
positivity. Based on this, approximately 33.6% of the African
volunteer serum samples were negative. ND50 titers in 46.6% of
the volunteers were between 29.3 and 120 (Fig. 2) and the
remaining 19.8% had CDV ND50 titers above 120 but below 800.
For comparison, serum from a ferret recently vaccinated with live-
attenuated CDV was 33,551. Similar to MV nAbs, CDV ND50 titers
were not signiﬁcantly different across gender. With the exception
of the volunteers from the Masaka CRC where higher CDV nAbs
(po0.001) were detected, no signiﬁcant difference was observed
for the other geographical regions. Although the CDV nAb titers
overall were low, positive CDV nAb values generally correlated
with higher magnitude MV titers (Fig. 3A, Spearman's ρ¼0.61,
po0.001). This relationship persisted when the correlation ana-
lyses were performed using nAb data that were stratiﬁed by
Table 1
Demographic characteristics of volunteers involved in the study (n¼146). CRC:
Clinical Research Center.
CRC Total Volunteer sex Volunteer age
Male Female
N % N % Median Mean Min Max
Kigali 30 14 46.7 16 53.3 27.5 30.2 20 50
Masaka 30 20 66.7 10 33.3 36.5 36.7 23 48
Kiliﬁ 26 13 50.0 13 50.0 32.5 32.2 20 46
Nairobi 30 17 56.7 13 43.3 26.5 29.0 20 41
Entebbe 30 15 50.0 15 50.0 30.5 30.1 19 45
Total 146 79 54.1 67 45.9 32.0 31.6 19 50
Fig. 1. Distribution of MV nAb titers. Negative threshold was deﬁned as the average
nAb titer of unvaccinated monkey serum plus 3 standard deviation. Functional
negative threshold was ND50 titer 120 since MV ND50 titers lower than that do not
prevent measles (Chen et al., 1990). For the 146 volunteers, 90.4% had MV titers
higher than 120 and majority of the titers were in ranges of 120.1–1000 (61.0%) and
1000–2000 (16.4%), which correspond to MV antibodies induced by vaccinations
(Hussain et al., 2013; Leuridan et al., 2010).
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volunteer enrollment site, gender, and age. Notably, the correlation
did not signiﬁcantly change when the analysis was performed
without including data points from Masaka CRC in which the
volunteers had higher CDV nAb titers (Fig. 3B, Spearman's ρ¼0.63,
po0.001). This indicated that the correlation relationship
between CDV and MV nAbs was general and was not due to this
individual CRC. Given the lack of epidemiologic evidence to
support frequent infection of CDV in humans, this result suggests
that CDV neutralization is due to cross-neutralizing MV antibodies,
which are present in low quantities and are detectable with the
CDV PRNT only in volunteers with relatively high MV ND50 titers.
A mutant CDV was generated that was more resistant to
neutralization by human serum
To better understand the molecular basis of the cross-neutra-
lization, a neutralization-resistant CDV mutant was isolated and its
genomic nucleotide sequence determined. The neutralization-
resistant CDV mutant was selected using a single healthy adult
donor serum of American origin that was available from a
commercial source and had detectable CDV and MV nAbs. The
neutralization-resistant CDV mutant grew in Vero cells with
similar kinetics as the progenitor virus (data not shown) indicating
that the escape mutation(s) had a little effect on replication in
culture. When the mutant was analyzed with the CDV PRNT using
25 serum samples randomly selected from the African volunteers,
it was more resistant to neutralization in all sera tested. Across the
25 samples, the ND50 titer determined with the mutant virus was
decreased by 2.1 fold compared to the progenitor CDV (Fig. 4A).
Genomic sequence analysis was performed on the resistant virus
population and 10 nucleotide substitutions were detected. Five of the
substitutions were in protein coding sequences but were silent in
terms of amino acid coding and one mutation was detected in the
trailer region (Table 2). Four mutations caused amino acid coding
changes with one in the fusion (F), one in the H and two in the large
polymerase (L) proteins. The F gene mutation resulted in a tyrosine
(Y) to serine (S) substitution at amino acid (aa) 48 in the signal
peptide (Fig. 5), while the H mutation resulted in a Y to aspartic acid
(D) substitution at aa537 (Fig. 6). The H amino acid substitution
occurred in a region that is involved in virus receptor interactions
and is conserved across morbilliviruses (Fig. 6).
The mouse monoclonal antibody 2F4 was used to conﬁrm that the
Y537D substitution altered antibody recognition in the receptor
binding region. The 2F4 antibody is speciﬁc for the receptor binding
region of MV H and is a potent neutralizer (Tahara et al., 2013). Stock
concentration of the 2F4 antibody used in this study was 1.85 mg/ml
and its neutralizing activity against MV was conﬁrmed. When the
antibody was tested in CDV PRNT, the dilution causing 50% neutraliza-
tion was determined to be 1017 and the calculated 50% inhibitory
concentration (IC50) was 1.8 mg/ml based on this dilution (Fig. 4B). In
contrast, the 2F4 antibody had a relatively little inhibitory effect on
infection with the CDV mutant as shown by the signiﬁcantly lower
PRNT value of 39.7, which was equivalent to IC50 of 46.6 mg/ml. These
results indicated that the Y to D substitution diminished binding by
antibody 2F4 in the receptor-binding region, suggesting that the
amino acid substitution had a similar effect on antibodies responsible
for neutralization activity in human serum.
Discussion
Results from this study showed that anti-CDV neutralizing
activity was relatively low or absent in sera from African clinical
trial volunteers. To our knowledge, this is the ﬁrst human
serosurvey involving a large number of volunteers conducted to
investigate the prevalence and potency of CDV nAbs. The results
Fig. 2. Distribution of CDV nAb titers. Negative threshold was deﬁned as the
average ND50 titer of unvaccinated ferret serum plus 3 standard deviation. Total
80.2% of the volunteers had CDV ND50 titers either below the negative threshold or
in 29.30–120 range.
Fig. 3. Strong correlation was found between MV and CDV nAb using Spearman's
rank correlation analysis. (A) Correlation statistics from analyzing MV and CDV nAb
titers of all 146 volunteers (Spearman's coefﬁcient ρ¼0.61, po0.001) suggest that
CDV neutralization is due to cross-reactive MV nAbs that are present at low
quantities in the volunteers who had relatively high MV nAb titers. Relationship
between log 10 transformed MV and CDV ND50 titers is shown by the ﬁtted line.
The shaded area represented 95% conﬁdence interval of the ﬁtted values.
(B) Analysis of the nAb values from the remaining 116 volunteers after excluding
data points of Masaka CRC still showed a strong correlation between the MV and
CDV nAb titers (Spearman's coefﬁcient ρ¼0.63, po0.001) and thus indicated that
the observed correlation was general and was not due to the individual CRC in
which the volunteers had relatively high level of CDV nAbs.
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also indicated that CDV neutralizing activity likely was related to
cross-reactive MV-speciﬁc antibodies. We analyzed a smaller
number of American serum samples obtained from a commercial
source and found their CDV neutralization potency was similarly
low (data not shown). CDV nAbs have been reported before, for
example in serum from subacute sclerosing panencephalitis (SSPE)
patients and in a small number of human samples, which were
shown to weakly neutralize a MV-CDV chimeric virus (Miest et al.,
2011; Sato et al., 1973), but these studies were not designed to
estimate the prevalence of anti-CDV neutralization. Our serosur-
vey results indicate that low level CDV nAbs can exist in a
signiﬁcant proportion of human populations probably induced
by MV vaccination or infection. This contrasts with data from dogs,
mice, and non-human primates vaccinated with live MV or vectors
expressing MV F and H proteins in which detectable CDV nAbs
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Fig. 4. Neutralization of CDV and the neutralization-resistant mutant by human
serum and mAb 2F4. (A) ND50 titers of serum. Dots on the left represent 25 serum
samples randomly selected from the 146 volunteers and the two lines represented
mean ND50 values to each virus. The average ND50 titer to mutant CDV was
2.1 fold lower than that to CDV indicating the mutant CDV was more resistant to
the serum neutralization. (B) IC50 of the 2F4 antibody. The bars represented
concentrations of the 2F4 antibody needed to neutralize 50% of the input CDV or
the CDV mutant. The highest dilution of the monoclonal antibody causing 50%
neutralization of CDV was 1017 and calculated IC50 was 1.8 mg/ml based on this
dilution. In contrast, the maximal dilution to neutralize 50% of the mutant virus
was only 39.7, which was equivalent to IC50 of 46.6 mg/ml, suggesting the Y to D
substitution in the receptor binding site of H diminished the antibody binding.
Table 2
Summary of nucleotide changes and amino acid substitutions between the CDV and
neutralization resistant CDV mutant.
Nucleotide differences between CDV and the neutralization resistant CDVa
ntb CDV Mutant CDV aa Substitutionc
M gene nt 3432–4439
3665 A G Silent
3707 A G Silent
3710 A G Silent
F gene nt 4935–6923
5077 A C Y to S
H gene nt 7079–8902
7786 T A Silent
8687 T G Y to D
L gene nt 9030–15,584
11,455 A G Q to R
14,298 A G I to V
14,324 C T Silent
Trailer nt 15,585–15,690
15,591 A G N/A
a Genomic cDNA sequences of the two viruses were compared. Uniform length
of 15,690 nt was achieved for each genomic cDNA after trimming sequence ends
and assembly.
b Nucleotide locations of genes and positions for nt changes in each gene
are shown.
c Amino acid coding substitutions caused by the nt changes are shown for
each gene.
Fig. 5. Mutation in F gene of the neutralization escape CDV isolate. A point mutation changed the tyrosine to serine at aa position 48 as highlighted in bold. The mutation
locates in signal peptide region of CDV F. The signal peptide is from amino acid 1–135 in precursor F protein (Plattet et al., 2007) and residues 1–50 are shown.
Fig. 6. Alignment of aa 501–547 of CDV H and corresponding regions in H proteins of MV, rinderpest virus (P09460), peste des petits ruminants virus (PPRV AHA58209),
dolphin morbillivirus (DMV Q66411) and phocine distemper virus (PDV P28882). Amino acid residues conserved among all 6 morbilliviruses are boxed. The CDV H is 607 aa
in length and the point mutation changed Y to D at aa position 537 (pointed by the triangular arrow) in H of the neutralization-resistant mutant. This sequence corresponds
to aa 505–551 in MV H (Masse et al., 2004), which is involved in H binding to MV receptors and is fully conserved among a variety of MV isolates including Edmonston,
Schwarz, Moraten and Zagreb vaccine viruses (H protein sequence accession # in GenBank: P08362, AAA566657, CAL40872, and AM237414, respectively).
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were not elicited although MV vaccination prevented infection or
disease progression following pathogenic CDV challenge (Appel
et al., 1984; de Vries et al., 2014; Taylor et al., 1991; Wild et al.,
1993). These results seem to suggest that MV vaccines induce
human antibodies that can cross-neutralize CDV, but that this is
less common in animal models.
Among the 146 volunteers in the survey, 66.4% were positive
for low CDV nAbs. This frequency of positivity suggests that MV
vaccination or MV infection is the likely inducer of the CDV nAbs,
although responses induced by CDV exposure cannot be ruled out.
Among the 5 CRCs in the survey, samples from the Masaka CRC
had the highest CDV nAb titers. This may be related to the rural
location of the Masaka site compared with the other 4 CRC
locations. It is conceivable that rural locality could increase the
risk of human CDV exposure due to a presence of unvaccinated
domestic dogs and wild animal species that are occasionally
infected by CDV during distemper outbreaks (Guiserix et al.,
2007; Leisewitz et al., 2001; van de Bildt et al., 2002). The
prevalence of higher titers in Masaka was not solely responsible
for the association between high MV titers and CDV neutralizing
antibodies as the same trend was seen if the Masaka data were
omitted from the statistical analysis.
The results showed that MV nAbs are prevalent since MV ND50
titers are all above the positive cutoff value of 8.63 that was
calculated based on average titers of a negative monkey serum
sample. In another study where PRNT was used for analysis of
clinical human samples, a titer of 8 was found to be the threshold
for detecting low levels of nAbs (Ratnam et al., 1995), which is
similar to our cutoff value. Although all of the samples we
analyzed were positive for MV antibodies, 9.6% had ND50 titers
lower than 120, which is the threshold for prevention of illness
due to measles virus infection (Chen et al., 1990). If we assume that
CDV ND50 titers greater than 120 are needed to inhibit infection
with a vector based on CDV, then 80.2% of the African volunteers
were below this threshold.
Two amino acid substitutions were identiﬁed in the glycoproteins
and two in the L protein of the CDV mutant that was selected for
increased resistance to human serum neutralization. Because the
membrane glycoproteins F and H are the only known targets of nAbs
(Orvell and Norrby, 1974, 1980), the L mutations likely did not
contribute to neutralization resistance. The F amino acid substitution
was located in the signal peptide that is present in the precursor
protein but absent in mature form, and therefore was considered less
likely to affect neutralization resistance (Plattet et al., 2007; von
Messling et al., 2004). H gene diversity is common and often
implicated in CDV evolution driven by immunologic pressure
(Martella et al., 2006; Sekulin et al., 2011; Trebbien et al., 2014).
The Y537D substitution in CDV H was located in a region that is
conserved among morbilliviruses and corresponds to amino acid
Y541 in MV H. This region of MV H contains residues involved in
binding to cellular CD46 and Nectin, and is associated with antibody
neutralization (Mateo et al., 2013; Santiago et al., 2010; Tahara et al.,
2013; Zhang et al., 2013a). Due to high sequence identity in this H
region, it is likely that nAbs induced by MV vaccination will bind the
same domain in CDV H, and our data indicates that the Y to D
substitution affected an epitope recognized by some cross-reactive
nAbs in human serum. This conclusion agrees with our results with
the MV H-speciﬁc monoclonal antibody 2F4, which we found to
neutralize CDV but was signiﬁcantly less active against the mutant
virus. It was evident that the Y537D substitution did not abolish
neutralization activity in human serum indicating that there were
other binding sites recognized by nAbs, which is consistent with
polyclonal nature of human antiserum against MV (Santibanez et al.,
2005, 2002).
The CDV H mutant might be useful for development of vaccine
vectors or oncolytic agents because it is less sensitive to pre-
existing MV-speciﬁc antibodies. Further characterization of the
mutant H incorporated in a recombinant CDV will be required to
determine if the Y537D substitution is stable during CDV propaga-
tion without constant application of selective pressure, if the
substitution is attenuating, and whether it alters receptor speciﬁ-
city. The general approach used to select the H mutant resistant to
human serum may also be valuable for developing modiﬁed
glycoproteins that are less susceptible to effects of anti-vector
immunity.
Materials and methods
Cell and virus
Vero cells were used in the CDV or MV plaque reduction
neutralization test (PRNT). The cells were maintained in Dulbec-
co's modiﬁed Eagle's medium (DMEM, Gibco) supplemented with
10% fetal bovine serum. The CDV used was a clonal isolate derived
from a commercial vaccine (Schering-Plough, USA) prepared from
the live-attenuated Onderstepoort virus. Isolation and culture of
the CDV mutant are described below. Neutralization sensitivity of
the mutant CDV was assessed with a subset of the serum samples
from clinical trial volunteers. MV used in these studies was an
attenuated Edmonston strain derived from a commercial vaccine
preparation (ATTENUVAX, MERCK & CO., USA). All three viruses
were propagated in Vero cells and plaque forming units (PFU)
were quantiﬁed as described previously for CDV (Zhang et al.,
2013b).
Serum samples
A total of 146 human serum samples were analyzed with the
CDV and MV PRNT. These samples were collected from three
eastern African countries from healthy adults, ages 19–50, enrolled
in vaccine-trial preparatory studies to determine regional HIV
incidence (Kamali et al., 2014). For CDV PRNT, sera from naïve
and CDV-vaccinated ferrets served as negative and positive con-
trols. Naïve and MV-vaccinated monkey sera were used for MV
PRNT controls. All serum samples were inactivated at 56 1C for
30 min before conducting the PRNT.
CDV and MV PRNT
The PRNT was conducted with CDV, mutant CDV, or MV
according to a standard MV PRNT protocol with slight modiﬁca-
tions (Cohen et al., 2007). Notably, infections were performed
using Vero monolayers instead of infecting cells in suspension.
Brieﬂy, four-fold serial dilutions were made with each serum
sample starting with a 1:4 dilution made by mixing 12.5 μl of
serum with 37.5 μl of DMEM in duplicate wells in 96-well plates.
The next dilution was made by transferring 12.5 μl of the diluted
serum samples to 37.5 μl of DMEM and so on. To each well of
diluted serum, an equal volume (37.5 μl) of CDV or MV solution
was added and incubated for 2 h. Thus, the ﬁrst serum dilution on
the plate was 1:8. For each experiment, either ferret or monkey
sera were used as negative and positive controls and were
processed in the same way as test samples. Vero cell monolayers
were prepared one day before in 24-well plates and were
approximately 80% conﬂuent the following day when they were
fed with 0.2 ml of fresh medium. After mixtures of virus and
diluted serum were incubated for 2 h to allow antibody binding,
the suspension (50 μl) was transferred from the 96-well plates to
the 24-well plates containing Vero cell monolayers. Following 2 h
virus adsorption, the medium was removed and cells were fed
with 1 ml DMEM containing 0.75% methylcellulose. Three days
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later, medium was removed and cells were washed once with PBS
and then ﬁxed with 100% cold methanol for 30 min. For viral
plaque detection, the cells were incubated with a rabbit antiserum
speciﬁc for CDV nucleoprotein or a commercial monoclonal anti-
body speciﬁc for MV nucleoprotein (AbCAM, USA). After removing
the primary antibody, incubation was conducted with anti-rabbit
or anti-mouse secondary antibodies conjugated with horse-radish
peroxidase (HRP). Staining was performed by addition of 3-Amino-
9-ethylcarbazole (AEC) substrate for HRP (Sigma). Average plaque
numbers were calculated from the duplicated wells at every
dilution for each serum sample. For determining neutralization
titers, the assay was standardized to generate about 30 plaques per
well when virus was treated without serum. At least four identical
wells were infected with the virus only for generating an average
plaque number in each experiment. Fifty percent neutralization
dose (ND50) titers were deﬁned as the reciprocal of the serum
dilution at which the number of plaques is reduced to 50% relative
to virus only controls. The calculation of ND50 titers followed the
Karber formula as described for MV PRNT (Cohen et al., 2007). The
serum samples were considered positive for CDV or MV nAbs if the
titers were greater than the average ND50 titer of the respective
naïve ferret or monkey serum plus 3 times the standard deviation.
The PRNT was conducted in the same way for the mouse
monoclonal antibody 2F4 except the starting dilution was 1:80
instead of 1:10 used in serum neutralization test due to limited
antibody availability. The 2F4 antibody is speciﬁc to the receptor
binding region of MV H protein and is a potent neutralizer to MV
(Tahara et al., 2013). Concentration of the antibody was 1.85 mg/ml
before dilution. Fifty percent inhibitory concentration (IC50) was
calculated for the 2F4 antibody according to dilutions needed to
neutralize 50% CDV.
Selection of neutralization escape mutants using human immune
serum
Neutralization resistant CDV was isolated using a commercial
human serum prepared from a single healthy adult donor in USA
(Innovative Research, USA). The serum sample was positive for
both MV and CDV neutralizing antibodies. A commercial human
serum was used because sufﬁcient quantity was available to make
it possible to conduct serial virus passage in the presence of nAbs,
and this also allowed us to preserve our limited quantities of
serum from the African volunteers. For selecting CDV mutants that
resisted neutralization, 1106 PFU of CDV in 1 ml of culture
medium was incubated with 200 ml of the undiluted serum in
37 1C incubator for 1 h, after which the virus was added to a Vero
cell monolayer cultured in T25 ﬂask (Nunc, USA). After 1 h
adsorption, the virus inoculum was replaced with 5 ml of cell
culture growth medium that was supplemented with 5% human
immune serum. Medium supernatant was harvested 6 days later
and 20% was used to infect a fresh monolayer that was subse-
quently incubated in medium containing 5% human immune
serum. The supernatant was harvested when a cytopathic effect
(CPE) appeared. Virus passage in the presence of human serum
was repeated 2 more times. After the 4th round of infection, virus
was analyzed with the PRNT using a subset of the African serum
samples. The genomes of parental and mutant CDV were
sequenced and compared.
Analysis of CDV genomic nucleotide sequences
Genomic sequences were determined by extracting RNA from
infected cell lysates, performing reverse transcription and PCR (RT-
PCR) using primers based on the CDV nucleotide sequence in GenBank
(accession number AF014953), and performing DNA sequencing on
ampliﬁed DNA fragments. Overlapping sequences were assembled and
analyzed using Vector NTI (version 11.5, Life Technologies). Genomic
sequences from CDV and the neutralization-resistant mutant were
aligned with ClustalW program in Lasergene software (DNASTAR Inc.).
Statistical analysis
Data analyses were conducted using Stata (v13.1, College
Station, TX, USA). Spearman's rank correlation analyses were
performed to determine the relationship between CDV and MV
nAb titers. Spearman's correlation coefﬁcient Rho and p values
were given. The titers were transformed to Log10 expression for
the correlation analyses and linear regression shown in Fig. 3. To
consider potential confounding geographical impact, CDV and MV
nAb data were stratiﬁed and the correlation analyses were con-
trolled for volunteer enrollment site, gender, and age at the time of
blood sample draw.
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